WO2016209021A1 - Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles - Google Patents
Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles Download PDFInfo
- Publication number
- WO2016209021A1 WO2016209021A1 PCT/KR2016/006754 KR2016006754W WO2016209021A1 WO 2016209021 A1 WO2016209021 A1 WO 2016209021A1 KR 2016006754 W KR2016006754 W KR 2016006754W WO 2016209021 A1 WO2016209021 A1 WO 2016209021A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- culture
- natural killer
- interleukin
- cell
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 186
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000002062 proliferating effect Effects 0.000 title abstract description 12
- 102000015696 Interleukins Human genes 0.000 claims abstract description 60
- 108010063738 Interleukins Proteins 0.000 claims abstract description 60
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 35
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 35
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 33
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 33
- 230000004663 cell proliferation Effects 0.000 claims abstract description 31
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 24
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 24
- 238000012258 culturing Methods 0.000 claims abstract description 18
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 61
- 102000000588 Interleukin-2 Human genes 0.000 claims description 57
- 108010002350 Interleukin-2 Proteins 0.000 claims description 57
- 238000007710 freezing Methods 0.000 claims description 37
- 230000008014 freezing Effects 0.000 claims description 37
- 102000016359 Fibronectins Human genes 0.000 claims description 34
- 108010067306 Fibronectins Proteins 0.000 claims description 34
- 108010074605 gamma-Globulins Proteins 0.000 claims description 30
- 239000001963 growth medium Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 16
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 10
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 9
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000001902 propagating effect Effects 0.000 claims description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 3
- 229930192851 perforin Natural products 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 102000004503 Perforin Human genes 0.000 claims description 2
- 108010056995 Perforin Proteins 0.000 claims description 2
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 239000007788 liquid Substances 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 108
- 239000000243 solution Substances 0.000 description 43
- 229940117681 interleukin-12 Drugs 0.000 description 29
- 230000035755 proliferation Effects 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 16
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 13
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- 101000889335 Bombyx mori Trypsin inhibitor Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000005880 cancer cell killing Effects 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- -1 and more preferably Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000005306 natural glass Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001939 mature NK cell Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- PJPOCNJHYFUPCE-UHFFFAOYSA-N picen-1-ol Chemical compound C1=CC=CC2=C(C=CC=3C4=CC=C5C=CC=C(C=35)O)C4=CC=C21 PJPOCNJHYFUPCE-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Definitions
- the present invention relates to a method for proliferating and killing natural killer cells, and to increasing the anticancer effect of proliferated natural killer cells.
- NK cells Natural killer cells used in immune cell therapy are morphologically large cells having large granules in the cytoplasm, and account for about 5-15% of lymphocytes in the blood.
- the main functions of NK cells that have been identified so far include the ability to kill tumor cells, cytotoxicity against virus infected cells, and the ability to kill bacteria and fungi.
- NK cells are expected to play an important role in antitumor, immunity and protective immunity against microorganisms.
- NK cells do not have cell surface receptors, such as T cell receptors, CD4 or immunoglobulins, and thus are classified as unique immune cells different from conventional T cells and B cells.
- NK cells are known to be cells that are capable of killing cancer nonspecifically.
- the killing ability of these NK cells can be used in the treatment of solid cancers with lymphokine activated killer cells (LAK) and tumor infiltration lymphocytes (TIL), or by donor lymphocyte infusion.
- LAK lymphokine activated killer cells
- TIL tumor infiltration lymphocytes
- donor lymphocyte infusion donor lymphocyte infusion.
- NK cells defects in the differentiation and activity of NK cells have been described in breast cancer (Konjevic G, et al., Breast Cancer Res. Treat., 66: 255-263, 2001), melanoma cancer (Ryuke Y, et al., Melanoma Res. , 13: 349-356, 2003), lung cancer (Villegas FR, et al., Lung Cancer, 35: 23-28, 2002), and has been reported to be associated with NK cells in the field of treatment of these diseases. Treatment is emerging.
- NK cells are only 5-15% of lymphocytes in the blood, even in normal humans. Especially in cancer patients, the number, differentiation and function of NK cells are often reduced, so that the number of cells is sufficient for treating diseases. It is difficult to secure.
- NK cells obtained according to the proliferation method of the conventionally developed NK cells have various deviations in proliferation rate and cytotoxic activity. Therefore, there is an urgent need for a method of proliferation or differentiation of new NK cells to secure a large amount of NK cells that maintain sufficient cancer cell killing ability.
- One object of the present invention is to provide a method for propagating natural killer cells with improved anticancer effect.
- Another object of the present invention is to provide a method for producing natural killer cells.
- Still another object of the present invention is to provide a pharmaceutical composition for treating or preventing cancer, including natural killer cells.
- Still another object of the present invention is to provide a composition for propagation of natural killer cells.
- One aspect provides a NK cell proliferation method comprising culturing NK cells in a culture medium comprising a first interleukin, a second interleukin, and an anti-NKp46 antibody.
- the first interleukin may be IL-2.
- the second interleukin may be at least one interleukin selected from the group consisting of interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18). Also preferably, the second interleukin may be IL-12, IL-18, IL-12 / IL-18, or IL-12 / IL-15 / IL-18, and more preferably, IL-18. have.
- IL-12 interleukin-12
- IL-15 interleukin-15
- IL-18 interleukin-18
- the NK cells may be cultured in a culture medium containing the first interleukin, the second interleukin, and the anti-NKp46 antibody in the presence of gamma globulin (IgG) and fibronectin.
- IgG gamma globulin
- fibronectin a culture medium containing the first interleukin, the second interleukin, and the anti-NKp46 antibody in the presence of gamma globulin (IgG) and fibronectin.
- the term “cell proliferation” means that the cells undergo a series of cell division steps to increase the number of cells in the culture or to differentiate the cells.
- the term “natural killer cell proliferation” means an increase in the number of NK cells in a culture through a series of cell division steps or by differentiation of immature blood cells into NK cells. Therefore, the "natural killer cell proliferation” may include an increase in the number of NK cells, or a state in which undifferentiated lymphocyte cells acquire NK cells to differentiate into NK cells or NK cells become mature NK cells in immature states. have.
- the NK cells which are the raw materials for the proliferation, can be purchased commercially or collected from humans or animals, and preferably supplied from humans in need of treatment with NK cells.
- the NK cells can also be supplied from any tissue source in vivo.
- the NK cells may be included in blood collected from a living body.
- the blood can be used as an NK cell source for application to the NK cell proliferation method of the present invention, as long as the blood comprises NK cells, and may be, for example, whole blood, umbilical cord blood, bone marrow, or peripheral blood.
- the natural killer cell proliferation may include, for example, culturing peripheral blood mononuclear cells.
- peripheral blood mononuclear cells PBMCs
- PBMCs peripheral blood mononuclear cells
- the PBMC can be prepared by a conventional manufacturing method from peripheral blood collected in vivo.
- the PBMC can be separated from peripheral blood using specific gravity centrifugation using Ficoll.
- the peripheral blood mononuclear cells may also be those obtained from an individual in need of treatment, that is, autologous peripheral blood mononuclear cells.
- the peripheral blood mononuclear cells are autologous peripheral blood mononuclear cells, even if some T cells exist in the proliferated NK cell population, since all cells are derived from the patient, there is an advantage of not having to remove the T cells.
- peripheral blood mononuclear cells used in the proliferation method of NK cells of the present invention may be frozen and preserved.
- the peripheral blood mononuclear cells can be isolated from blood, frozen and thawed again to use for NK cell proliferation.
- the freezing may use a conventionally known method, preferably the first freezing step in the range of 4 to -42 °C, the second freezing step in the range of -42 to -15 °C, and -15 to -120 °C It can be frozen by a freezing method consisting of a third freezing step.
- each freezing step can raise or lower the temperature to the upper limit or the lower limit of the temperature range of each freezing step by maintaining the sample sequentially for a predetermined time at several discontinuous temperatures within the temperature range.
- the first freezing step is frozen under conditions of 10-15 minutes at 0 ° C., 5-10 minutes at ⁇ 12 ° C., and 0.5-1 minute at ⁇ 42 ° C.
- the second freezing step comprises: After the freezing step 1 to freeze at -25 °C for 1 to 3 minutes, and -15 °C for 1 to 3 minutes, the third freezing step after the second freezing step at -42 °C 20 to 40 minutes and -120 It may be made of a process of freezing at 20 °C to 50 minutes conditions.
- the first freezing step is frozen at 0.5-5 ° C./m in the range of 4-40 ° C.
- the second freezing step is 1-10 in the range of ⁇ 40-90 ° C. after the first freezing step.
- the third freezing step may be made of a process of freezing to the conditions of 1 ⁇ 10 °C / m in the range of -90 ⁇ -120 °C after the second freezing step.
- Each freezing step of the freezing method may be performed by a controlled rate freezer (CRF).
- CRF controlled rate freezer
- the cryopreserved peripheral blood mononuclear cells can be provided for culturing and proliferating NK cells according to the present invention after thawing, and can be used after culturing and proliferating at a desired time after collecting blood from the patient by undergoing a freezing process.
- a freezing method and thawing method of peripheral blood mononuclear cells that can be effectively applied to the culture method of activated NK cells. Accordingly, a large amount of blood can be secured, separated and frozen and stored when the patient's condition is good, thereby enabling regular production and administration of NK cells regardless of the patient's condition.
- the NK cell proliferation method may culture NK cells in the presence of gamma globulin (IgG) and fibronectin.
- the culture in the presence of gamma globulin and fibronectin is, for example, in a culture container containing gamma globulin and fibronectin in the culture solution or coated with gamma globulin and fibronectin on the culture surface (the surface of the culture container that can come into contact with the cells). It may be to culture the cells.
- the NK cells may be cultured in a culture vessel coated with gamma globulin and fibronectin.
- the culture vessel coated with gamma globulin and fibronectin may be prepared by adding a solution containing gamma globulin and fibronectin.
- a known adhesive protein may be used in place of the fibronectin, for example, collagen or the like may be used.
- a solution containing gamma globulin and fibronectin is added to a culture vessel (e.g., a T75 flask), followed by incubation at low temperature (e.g., 2-4 ° C) to coat the culture vessel with gamma globulin and fibronectin. Can be done.
- the concentration of gamma globulin may be 0.1-1 ng / ml, 1-10 ng / ml, 10-100 ng / ml or 1-100 ng / ml.
- Gamma globulin can activate NK cells by stimulating Fc ⁇ RIII of NK cells.
- the concentration of fibronectin may be 0.1-50 ⁇ g / ml, 1-50 ⁇ g / ml, 5-50 ⁇ g / ml, 10-50 ⁇ g / ml. Fibronectin may promote the migration of NK cells and facilitate the interaction between cells.
- the NK cell proliferation method includes NK cells in a first interleukin (interleukin-2 (IL-2)), a second interleukin (interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin.
- IL-2 interleukin-2
- IL-12 interleukin-12
- IL-15 interleukin-15
- interleukin interleukin.
- the culture solution may include an anti-NKp46 antibody, a second interleukin, and IL-2 in a conventional immune cell culture medium.
- the medium for immune cell culture include ALyS505NK-EX (Cell Science & Technology Inst.
- Culture medium such as KBM (Kohjin bio, Japan) can be used.
- the above-mentioned anti-NKp46 antibody, second interleukin, and IL-2 of natural killer cells can be added to the above-mentioned immune cell culture medium to prepare a culture solution for use in one embodiment of the present invention.
- the anti-NKp46 antibody and the second interleukin can also be prepared by adding a commercial medium for immune cell culture containing IL-2.
- the culture medium may be used without limitation as long as the medium for the immune cell culture containing the second interleukin, anti-NKp46 antibody and IL-2.
- the concentration of IL-2 in the culture medium is 500-5,000 IU / mL, 600-4,000 IU / mL, 700-3,000 IU / mL, 800-2,000 IU / mL, 900-1,500 IU / mL, 900-1,200 IU. / Ml or 1,000-1,200 IU / ml.
- the IL-2 may promote growth of NK cells.
- the concentration of the anti-NKp46 antibody included in the culture solution may be 0.1 to 10 ⁇ g / ml, 0.5 to 10 ⁇ g / ml, 1 to 10 ⁇ g / ml, or 5 to 10 ⁇ g / ml.
- NKp46 is an activating receptor for NK cells, whereby the anti-NKp46 antibodies of the present invention can stimulate NKp46 to activate NK cells.
- the concentration of the second interleukin contained in the culture solution is 0.1-100 ng / ml, 1-100 ng / ml, 10-100 ng / ml, 20-100 ng / ml, 30-100-100 ng / ml, 50-100 ng / ml, or 70-100 ng / ml.
- the second interleukin of the present invention is a component that can not only increase the proliferation efficiency of NK cells, but also greatly increase the activation of NK cells.
- the present invention uses a second interleukin in addition to the IL-2 and anti-NKp46 antibodies, thereby enhancing and synergistic the proliferation and activation of NK cells possessed by the IL-2 and anti-NKp46 antibodies, thereby increasing existing NK cell proliferation. Compared to the method can have a better proliferation effect of NK cells.
- the combination of IL-2, the second interleukin, and the anti-NKp46 antibody which are components included in the composition for NK cell proliferation of the present invention, can maximize the proliferation and culture efficiency of NK cells. It will also be very cost effective.
- the culture may further comprise plasma or serum.
- plasma or serum contained in the culture solution may be obtained from peripheral blood obtained by separating PMBC used for NK cell culture.
- the concentration of plasma may be 1-20 v / v%, 1-15 v / v%, 2-15 v / v%, 5-15 v / v%, or 5-10 v / v% days for the whole culture. Can be.
- PBMCs and plasma are respectively isolated from peripheral blood of a patient to which NK cells are administered, and the obtained PBMCs are isolated from the IL-2, second interleukin, anti-NKp46 antibody, and the peripheral blood. It may be cultured in a medium containing plasma (or serum). In addition, the culture is preferably cultured in a culture vessel coated with gamma globulin and fibronectin.
- Cultivation of the peripheral blood mononuclear cells can be carried out under normal cell culture conditions, that is, about 37 °C, CO 2 incubator, the culture medium can be continuously added while adding every two or three days.
- concentration of PBMC added to the medium may range from 4 X 10 5 to 5 X 10 7 cells / mL, but is not limited thereto.
- the incubation period may be performed, for example, for 7 to 20 days, 8 to 18 days, 10 to 16 days, 10 to 15 days, or 10 to 14 days, but is not limited thereto.
- the culture days may be appropriately set within or outside the range.
- Culture vessels may include commercially available dishes, flasks, plates, multi-well plates, culture bags.
- the culture can be cultured in each step in order to maximize the growth of NK cells.
- each culture step may be the same or different culture medium components, culture vessels and culture periods, the final growth of NK cells can be achieved by finding the optimum culture period for each step.
- the present invention is characterized in that the culture composition (or culture medium) is added to the flask at intervals of 2-3 days in the flask, thereby culturing the NK cells effectively.
- the NK cell proliferation method of the present invention comprises a culture medium containing peripheral blood mononuclear cells, a first interleukin, a second interleukin, an anti-NKp46 antibody, and a plasma in a culture vessel coated with gamma globulin and fibronectin. 1 culture step; And a second culture step of culturing by further adding a culture solution including a first interleukin, a second interleukin, an anti-NKp46 antibody, and a plasma to the culture obtained from the first culture step.
- the first interleukin may be interleukin-2 (IL-2).
- the second interleukin may be at least one interleukin selected from the group consisting of interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18).
- IL-12 interleukin-12
- IL-15 interleukin-15
- IL-18 interleukin-18
- the first interleukin and the second interleukin are as described above.
- the plasma may be obtained from peripheral blood derived peripheral blood mononuclear cells. Serum may be used instead of the plasma.
- the concentration of IL-2 contained in the culture medium in the first culture step is 500-5000 IU / mL, 600-4000 IU / mL, 700-3000 IU / mL, 800-2000 IU / mL, 900-1500 IU / mL , 900-1,200 IU / mL or 1,000-1,200 IU / mL.
- Said first culture step comprises a first interleukin (IL-2), a second interleukin (at least one interleukin selected from the group consisting of IL-12, IL-15, and IL-18), anti-NKp46 antibodies and plasma
- IL-2 interleukin
- second interleukin at least one interleukin selected from the group consisting of IL-12, IL-15, and IL-18
- anti-NKp46 antibodies and plasma
- Peripheral blood mononuclear cells may be cultured for 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days in a culture medium containing, for example, 3 days, 4 days May be incubated for 5 days, 6 days, preferably 5 days.
- the NK cell proliferation method according to the present invention may further include adding a culture solution including IL-2 and plasma to the culture during the first culture step.
- the culture solution further comprising IL-2 and plasma added above may be added on the third day of culture and / or on the fourth day of culture.
- the concentration of IL-2 included in the additionally added culture solution may be the same as the concentration of IL-2 in the culture solution of the first culture step, but is not limited thereto.
- the volume of the culture added may be the same as the volume of the culture.
- NK cell cell proliferation method of the present invention is a group consisting of a first interleukin (IL-2), a second interleukin (IL-12, IL-15, and IL-18) in a culture obtained from the first culture step in one embodiment And a second culture step of culturing by further adding a culture solution comprising at least one interleukin selected from C), an anti-NKp46 antibody and plasma.
- IL-2 interleukin
- IL-12, IL-15, and IL-18 interleukin
- the second culture step may be performed by transferring the culture of the first culture step to a new container.
- the new container may not contain gamma globulin and fibronectin.
- the concentration of IL-2 in the culture medium of the second culture step may be the same as the concentration of IL-2 in the culture solution of the first culture step, but is not limited thereto.
- the concentration of IL-2 contained in the culture medium in the second culture step is 500-5,000 IU / mL, 600-4,000 IU / mL, 700-3,000 IU / mL, 800-2,000 IU / mL, 900-1,500 IU / Ml, 900-1,200 IU / ml or 1,000-1,200 IU / ml.
- the culture comprising the antibody and plasma may be the same volume as the culture.
- the cells may be cultured in the culture solution for 1 day, 2 days, 3 days, 4 days, 5 days, or 6 days, preferably 1 day, 2 days, or 3 days. have.
- the NK cell proliferation method of the present invention may further include a third culture step of culturing after lowering the concentration of IL-2 in the culture to 4/5 or less than 1/10 of the concentration before adding the culture.
- the IL-2 concentration is for example 1/100 to 3/5, 1/100 to 1/4, 1/100 to 2/5, 1/100 to 1/3, or 1 / 100 to 1/5.
- Lowering the concentration of IL-2 in the culture solution may be performed by adding a culture medium not containing IL-2 to the culture.
- the culture solution added in the third culture step may include plasma.
- IL-2 concentration of the culture in the third culture step is 1500-1300 IU / ml, 1300-1000 IU / ml, 1000-600 IU / ml, 600-500 IU / ml, 500-400 IU / ml, 400 -300 IU / mL, 300-200 IU / mL, 200-100 IU / mL.
- the culture solution of each culture step may contain appropriate proteins, cytokines, antibodies, compounds and other components provided that they do not impair the effect of amplifying NK cells.
- the proliferated cells may be to express any one or more selected from the group consisting of CD56, CD16, NKG2D, Perforin and Granzyme B.
- the expression may be to express more of the factor compared to the peripheral vascular blood cells or cell population before proliferation, or the natural killer cells or cell population before proliferation.
- the peripheral vascular blood cells or cell populations comprising the proliferated natural killer cells, or the proliferated natural killer cells or cell population may comprise at least 70% or more of the above factors in the whole cell or in the entire cell population. It may be at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 99%, or 100%.
- the "% expression” or “expression rate” may refer to the percentage of NK cells expressing one or more of the factors relative to the total number of cells in the sample.
- the expression or expression rate of the factor in the cell or cell population can be determined by the value detected using a flow cytometer.
- the present invention may further provide a method of producing the method comprising the step of suspending NK cells proliferated by the NK cell proliferation method in a solution containing dextran and albumin. .
- NK cells proliferated by the NK cell proliferation method of the present invention expressed a high level of anticancer substances compared to PBMC, and showed excellent anticancer activity (see FIGS. 7 to 9).
- Another aspect provides a pharmaceutical composition for treating or preventing cancer comprising the proliferated NK cells.
- the NK cells and the proliferation method of the NK cells included in the pharmaceutical composition are as described above.
- the subject may be a mammal and may comprise a human.
- the cancer may be leukemia, breast cancer, ovarian cancer, brain cancer, melanoma cancer, gastric cancer, liver cancer, colon cancer or lung cancer, but is not limited thereto.
- the pharmaceutical composition may include a cell population including NK cells cultured according to the NK cell proliferation method.
- the composition may include a culture solution or culture used for culturing in addition to the cell population cultured according to the above method.
- the composition may comprise a new culture or physiological saline that does not contain additional components such as cytokines and cell populations isolated from the culture.
- the new culture medium may be a medium having the same composition as the medium used for culturing NK cells or a medium having a different composition.
- the dosage of NK cells varies depending on the condition and weight of the cancer patient, the extent of the disease, the dosage form, the route of administration, and the duration, for example, 1 ⁇ 10 6 to 1 ⁇ 10 per day.
- the dose may be administered at a dose of 1 ⁇ 10 7 to 1 ⁇ 10 9 cells / kg.
- the administration may be administered once or several times a day.
- liquid unit preparations such as liquids, suspensions, emulsions, and the like, it may also be administered to the patient at the cell concentration.
- the pharmaceutical composition according to the present invention includes NK cells proliferated by the method of the present invention as described above, and may further include a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be formulated in parenteral formulations, such as liquids, suspensions, emulsions, lyophilizers, etc. according to conventional methods.
- the pharmaceutically acceptable carrier may include an aqueous diluent or a solvent such as phosphate buffered saline, purified water or sterile water. And other conventional preservatives.
- the pharmaceutical composition may include various anti-tumor agents or other therapeutic agents in addition to the NK cells or a cell population including NK cells.
- Another aspect provides a method of treating or preventing cancer comprising administering such proliferated NK cells to a subject.
- the subject and cancer are as described above.
- the route of administration may be administered orally or parenterally (eg, by injection), and the injection may be intravenous, subcutaneous, intramuscular or intraperitoneal. It may be, but is not particularly limited thereto.
- Another aspect provides the use of said propagated NK cells for the manufacture of a medicament for the treatment or prevention of cancer.
- Another embodiment is one kind selected from the group consisting of a first interleukin (IL-2), a second interleukin (interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18) It provides a composition for NK cell proliferation comprising the above interleukin) and anti-NKp46 antibody.
- IL-2 interleukin
- IL-12 interleukin-12
- IL-15 interleukin-15
- IL-18 interleukin-18
- Another embodiment is a first interleukin (IL-2), a second interleukin (interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-) for the preparation of a composition for NK cell proliferation 18) and at least one interleukin selected from the group consisting of 18) and anti-NKp46 antibodies.
- IL-2 interleukin
- IL-12 interleukin-12
- IL-15 interleukin-15
- IL-18 interleukin-18
- the composition for proliferating NK cells may further include gamma globulin and fibronectin.
- the first interleukin and the second interleukin are as described above, respectively.
- the concentration of IL-2 in the proliferation composition is 500-5000 IU / mL, 600-4000 IU / mL, 700-3000 IU / mL, 800-2000 IU / mL, 900-1500 IU / mL, 900-1,200 IU. / Ml or 1,000-1,200 IU / ml.
- the concentration of the second interleukin in the growth composition is 0.1-100 ng / ml, 1-100 ng / ml, 10-100 ng / ml, 20-100 ng / ml, 30-100-100 ng / ml, 50-100 ng / ml, or 70-100 ng / ml.
- the concentration of the anti-NKp46 antibody in the proliferation composition may be 0.1 to 10 ⁇ g / ml, 0.5 to 10 ⁇ g / ml, 1 to 10 ⁇ g / ml, or 5 to 10 ⁇ g / ml.
- composition for proliferating NK cells may be for proliferating or differentiating NK cells in peripheral blood mononuclear cells.
- the composition for proliferating NK cells may further include plasma or serum.
- the plasma or serum added to the composition may be obtained from blood from which NK cells are separated.
- the plasma contained in the composition for proliferation may be obtained from peripheral blood mononuclear cells isolated peripheral blood.
- the proliferating composition comprises gamma globulin, fibronectin, first interleukin (IL-2), second interleukin (at least one interleukin selected from the group consisting of IL-12, IL-15, IL-18) and anti-NKp46 antibodies
- IL-2 first interleukin
- second interleukin at least one interleukin selected from the group consisting of IL-12, IL-15, IL-18
- anti-NKp46 antibodies In addition to the components, it may include essential components or other carriers or adjuvants for PBMC culture and NK cell proliferation.
- Natural killer cell proliferation method or a composition for natural killer cell proliferation can promote the proliferation and differentiation of natural killer cells, and can stably provide natural killer cells with increased cytotoxic activity.
- the natural killer cells thus prepared may be usefully used for the treatment of diseases such as anticancer treatment.
- 1 is a result of the proliferation of the total cell number (A) and NK cell number (B) by the proliferation method according to an embodiment of the present invention.
- 3 is a result showing the effect of NK cell proliferation according to IL-2 concentration.
- FIG. 5 is a flow cytometry result of NK cells by the proliferation method according to an embodiment of the present invention.
- Figure 6 shows the results showing the activation receptor of NK cells obtained according to one embodiment using a flow cytometer.
- Figure 7 is a graph showing the flow cytometry results for confirming the expression of anticancer substances in NK cells obtained according to one embodiment.
- FIG. 8 shows the results of evaluating cancer cell killing% of K562 cells, which are leukemia cell lines of NK cells obtained according to various embodiments, by a flow cytometry method.
- Figure 9 shows the results of evaluating the cancer cell lysis (% cell lysis) of the NK cells obtained according to one embodiment by a flow cytometry method. Cancer cell killing for K562 (chronic leukemia), OVCAR3 (ovarian cancer), Hep3B (liver cancer), HepG2 (liver cancer), A704 (renal cancer), DU145 (prostate cancer).
- PBMC 10 shows the pre-culture PBMC characteristics of Donor 1.
- A. Proportion of NK cells (Q9, CD3-CD56 +), B. CD16 expressing NK cells (Q2, CD16 + CD56 +), C. B cells (Q5, CD3-CD19 +), D. K562 cells, cytotoxicity (7AAD + , E: T 10: 1)
- Blood was prepared by collecting blood from normal veins. At this time, the blood collection vessel used a blood collection tube containing heparin. Blood from the patient was carefully transferred to 30 ml each of two tubes (# 352070, BD or equivalent) containing Ficoll (# 17-1440-02, GE Healthcare or equivalent). The tube containing blood was centrifuged at 2,500 rpm for 10 minutes in a break off state, and then the upper plasma portion was transferred to a new tube.
- the transferred plasma was inactivated for 30 minutes in a heat block, and then centrifuged for 5 minutes at 4,000 rpm.
- the supernatant from the centrifuged tube was transferred to a new tube, labeled as plasma, and stored at 2 to 8 ° C.
- the cell suspension was centrifuged at 1,500 rpm for 5 minutes to remove the supernatant, and Ca / Mg free DPBS was added to the tube from which the supernatant was removed, followed by further centrifugation at 1,500 rpm for 5 minutes. The supernatant was removed and the remaining precipitated cells were suspended in 1 ml of Alys505NK-EX (# 01410P10, CSTI) medium.
- Example 1.1 All the cell suspensions obtained in Example 1.1 were centrifuged at 1,500 rpm for 5 minutes and the supernatant was removed. The cells were suspended in a Cryostor CS10 or ALyS505NK-EX + Albumin + DMSO mixed solution stored at 2 to 8 ° C. to give a cell number of 1-100 ⁇ 10 6 cells / ml. Dispense the suspended cells in 1 ml into 2 ml cryogenic vials and then use controlled rate freezers (CRF) for 10-15 minutes at 0 ° C, 5-10 minutes at -12 ° C, and -42 ° C. Frozen in a first step under conditions of 0.5 to 1 min at 1 to 3 minutes at ⁇ 25 ° C.
- CRF controlled rate freezers
- the second step was frozen at a condition of 5 ° C./m in the range of ⁇ 90 ° C., and was frozen at 5 ° C./m in the range of ⁇ 90 ° to 120 ° C. after the second freezing step.
- Frozen cells were transferred to LN 2 tanks and stored (below -130 ° C).
- the heat block was set to 37 ° C., and then a culture solution with 10% plasma was added to the T flask. Depending on the cell concentration, the culture volume can be variously adjusted to, for example, 4ml, 6ml, 8ml, or 10ml.
- the frozen PBMC which was frozen in Example 2.2, was placed in a heat block to dissolve frozen PBMCs. When the frozen PBMC was half dissolved, it was transferred to a T flask containing the culture. Subsequently, it was placed in a 37 ° C., 5% CO 2 incubator and incubated for one day.
- the cultured PBMCs were collected in a tube, Ca / Mg free DPBS was added, centrifuged at 1,500 rpm for 5 minutes, and the supernatant was removed. Cells isolated by centrifugation were suspended in a small amount of culture and cell number was measured. The viability after thawing of cryopreserved cells is shown in Table 1. As can be seen in Table 1, thawed PMBC after cryopreservation according to the present invention was found to survive 93% or more, it was confirmed that high survival rate is maintained.
- fibronectin # FC-010, Millipore
- 0.121 mL gamma globulin # 020A1004, Green Cross
- the prepared coating solution was put into a T75 flask (# 156499, Nunc) using a pipette and reacted at 2 to 8 ° C. for at least 16 hours. The remaining coating solution was washed with Ca / Mg free DPBS before cell culture and then removed.
- Example 2.1.1 10 ⁇ l of the amount of fibronectin in Example 2.1.1, A culture flask coated with fibronectin and gamma globulin was prepared in the same manner as in Example 2.1.1 except that only 1.21 ml of gamma globulin was changed.
- fibronectin # FC-010, Millipore
- Example 1 The cell suspension prepared in Example 1 was taken and placed in the coating flask prepared in Example 2.1, and 1.5 ml of autologous plasma and 0.03 ml of anti-NKp46 (# MAB1850, R & D) solution, IL-18 (# B003-2, R & D) 0.075 mL and 13.4625 mL of Alys505NK-EX (# 01410P10, CSTI) were added and incubated in a CO 2 incubator for 2-3 days. After that, 1.5 ml of autologous plasma and 13.5 ml of Alys505NK-EX were added to the flask and incubated in a CO 2 incubator for 1-2 days.
- Example 2.2.1 All procedures were the same as in Example 2.2.1, except that 3 ⁇ l of anti-NKp46 (homologous) solution, 37.5 ⁇ l of IL-18 (homologous), and 2 times of Alys505NK-EX were used and a total of 35.95 mL was used. .
- Example 2.2.1 All procedures are the same as in Example 2.2.1 except that 15 ⁇ l of anti-NKp46 (homologous) solution, 7.5 ⁇ l of IL-12 (# 554613, BD) and 2 times of Alys505NK-EX were used and a total of 26.98 ml was used. It was carried out by.
- Example 2.2.1 All procedures are the same as in Example 2.2.1, but 0.03 ml of anti-NKp46 (homologous) solution, 7.5 ml of total IL-12 (homologous), and 12.5 ⁇ l of IL-15 (# 247-IL-0025, R & D) A total of 37.5 ⁇ l of IL-18 and 2 times of Alys505NK-EX were added and 26.913 mL of total was used.
- Example 2.2.1 After the primary culture of Example 2.2.1, the T75 flask in which the cells were cultured was taken out of the incubator, and the cells were collected and transferred to a T175 flask (# 159910, Nunc). 3 ml of autologous plasma and 27 ml of Alys505NK-EX (# 01410P10, CSTI) were added to a T175 flask and incubated for 1-2 days in a CO 2 incubator.
- Example 2.3.1 All procedures were the same as in Example 2.3.1 except that 0.06 ml of anti-NKp46 (# MAB1850, R & D) solution, 0.06 ml of IL-18 (# B003-2, R & D), and 53.88 ml of Alys505NK-EX were used. Secondary culture of the culture of Example 2.2.2 was performed.
- Example 2.3.1 All procedures are the same as in Example 2.3.1, except for using 0.12 ml of anti-NKp46 (# MAB1850, R & D) solution, 0.03 ml of IL-12 (# 554613, BD), and 53.85 ml of Alys505NK-EX. Second culture of .3 culture was performed.
- Example 2.3.1 All procedures were the same as in Example 2.3.1, using 0.06 mL of anti-NKp46 (# MAB1850, R & D) solution, 0.03 mL of IL-12 (homologous), 0.02 mL of IL-18 (homologous), 44.89 mL of Alys505NK-EX Secondary culture of the culture of Example 2.2.4 was carried out except for the following.
- Example 2.3.1 All procedures are the same as in Example 2.3.1, except for 0.06 mL of anti-NKp46 (# MAB1850, R & D) solution, 0.03 mL of IL-12 (homologous), 0.06 mL of IL-15 (homologous), 0.02 mL of IL-18 (homologous) 0.02
- the second culture of the culture of Example 2.2.5 was performed except that 62.83 ml of Alys505NK-EX was used.
- the cells of the T175 flask and the autologous plasma cultured in Example 2.3 were placed in a culture solution containing 300 IU / ml IL-2, and cultured in a CO 2 incubator. After 2-3 days a new equal volume of culture (culture containing 300 IU / ml IL-2) was mixed with the cell suspension in which the cells were incubated and then cultured in a CO 2 incubator.
- IL-2 is added to the immune cell culture medium without IL-2 in a predetermined amount instead of the culture medium to which IL-2 is added, respectively. It may be.
- Example 2.4 After all the cells cultured in Example 2.4 were collected, the supernatant was removed by centrifugation at 1500 rpm for 5 minutes and then suspended in phosphate buffered saline. 10 ⁇ l of the cell suspension was diluted with phosphate buffered saline, and then 10 ⁇ l of the diluted solution was mixed with 10 ⁇ l of trypan blue and placed on a hemocytometer to measure cell number and viability. The cell number was determined by the formula (live cell number + dead cell number) ⁇ 1/4 ⁇ 2 ⁇ dilution factor ⁇ total volume ⁇ 10 4 , and cell viability was determined as viable cell number ⁇ (live cell number + dead cell number) ⁇ 100 Obtained by the formula
- IL-12, IL-15, or a mixture of IL-12 and IL-15, or IL-18 has been shown to be effective in raising the NK ratio.
- Example 1 The cell suspension prepared in Example 1 was taken and placed in the coating flask prepared in Example 2.1, and 1.5 ml of autologous plasma and 0.03 ml of anti-NKp46 (# MAB1850, R & D) solution, IL-18 (# B003-2, R & D) 0.075 mL, 13.4625 mL of Alys505NK-EX (# 01400P10, CSTI) without IL-2 was added, and IL-2 was added at a concentration of 0 to 10,000 IU / mL (see FIG. 3) in a CO 2 incubator for a total of 14 Incubated daily.
- anti-NKp46 # MAB1850, R & D
- IL-18 # B003-2, R & D
- Alys505NK-EX # 01400P10, CSTI
- NK cells cultured for 14 days were centrifuged at 1500 rpm for 5 minutes to remove supernatant and then suspended in phosphate buffered saline. Ten microliters of the suspended cells were taken, diluted with phosphate buffered saline, and 10 microliters of the diluted solution was mixed with 10 microliters of trypan blue and placed on a hemocytometer to measure the cell number. The cell number measurement method is the same as in Example 3.1. The number of NK cells was calculated from the percentage of NK cells obtained through flow cytometry. The IL-2 concentration of 100 IU / ml was set to 1, and the fold proliferation of NK cells following the remaining IL-2 concentration treatment was calculated.
- Example 1 The cell suspension prepared in Example 1 was added to the prepared 96 well plate, and 10 ⁇ l of autologous plasma, 0.2 ⁇ l of anti-NKp46 (# MAB1850, R & D) solution, and 1000 IU / ml of IL-2 were added to Alys505NK-EX. 89.8 ⁇ l (# 01410P10, CSTI) was added, IL-12 was added at a concentration of 0-10 ng / ml (see FIG. 4A), and IL-18 was added at a concentration of 0-300 ng / ml (see FIG. 4B). Incubated for 48 hours in a CO 2 incubator.
- NK cells were transferred to a new tube and centrifuged at 1,500 rpm for 5 minutes to transfer only the supernatant to a new tube.
- the activity of NK cells was confirmed by IFN-gamma secretion using IFN-gamma ELISA kit (# DIF50, R & D).
- IL-12 secreted high IFN-gamma at a concentration range of 0.1 to 10 ng / ml and IL-18 secreted high IFN-gamma at a concentration of 1 to 100 ng / ml. was measured.
- NK cells cultured and harvested in Example 2 were analyzed using flow cytometry. Specifically harvested cells were suspended in Ca / Mg free DPBS, centrifuged at 1500 rpm for 5 minutes, then the supernatant was removed to obtain cell pellets. Antibody (CD3-FITC, CD56-APC, CD16-PE) containing fluorescent material was added to the obtained cell pellet, and then incubated at 4 ° C. for 20 minutes. FACS buffer was added and centrifuged once for 1 minute at 8,000 rpm, and analyzed by flow cytometry (FACSCalibur, BD), and the results are shown in FIG. 5.
- cells grown according to one embodiment express more CD56 and CD16 and less CD3 than PBMCs before proliferation.
- NK cells were stained with fluorescent materials.
- Antibodies KIRDL1-PE, NKG2A-PE, NKG2D-PE, NKp30-PE, NKp44-PE, NKp46-PE
- FACS buffer was added and centrifuged once for 1 minute at 8000 rpm, and analyzed by flow cytometry (Guava 8HT, merk), and the results are shown in FIG. 6.
- the cells proliferated according to one embodiment it can be seen that express more NKG2D, NKp30, NKp44, or NKp46 than PBMCs before proliferation.
- the proliferated cells express more perforin, granzyme B, or TRAIL than PBMCs before proliferation.
- Hep3B, OVCAR3, HepG2, A704, DU145 various solid cancer cell lines
- leukemia cell lines Hep3B, OVCAR3, HepG2, A704, DU145
- Cells were prepared by adding the culture solution to the washed cell pellet at a concentration of 5 ⁇ 10 5 cells / ml. Prepared cells were treated with CFSE (# c34554, Life technologies) and incubated for 10 minutes in a CO 2 incubator.
- the cells were washed twice with Ca / Mg free DPBS and then treated with the prepared NK cells and incubated for 4 hours in a CO 2 incubator. 10 minutes before the end of incubation, 7AAD was treated and after the end of incubation, cells were harvested in vitro and analyzed for cancer cell killing ability by flow cytometry (FACSCalibur, BD). Cancer cell killing value was calculated by the following formula.
- Cytotixicity (%) (sample-group-natural glass) / (100-natural glass) ⁇ 100
- K562 lysis results are shown in FIG. 9 and Table 2, and lysis results for various solid cancer cell lines are shown in FIG. 9.
- the use of anti-NKp46 combination in a flask coated with fibronectin and gamma globulin showed high K562 elimination efficacy, OVCAR3 (ovarian cancer), Hep3B (liver cancer), HepG2 (liver cancer), A704 (renal cancer), DU145
- OVCAR3 ovarian cancer
- Hep3B liver cancer
- HepG2 liver cancer
- A704 renal cancer
- DU145 In various solid cancers such as (prostate cancer), the removal efficiency increased according to the E: T ratio (the number of effect cells: the number of target cells).
- the effector cell refers to NK cells
- the target cell refers to cancer cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une méthode pour faire proliférer des cellules tueuses naturelles et une composition pour faire proliférer des cellules tueuses naturelles, capable d'améliorer l'activité de prolifération cellulaire et l'activité anticancéreuse, la méthode comprenant une étape de culture de cellules tueuses naturelles dans un milieu de culture liquide contenant une première interleukine (l'IL-2), une seconde interleukine (au moins une interleukine sélectionnée au sein du groupe constitué par l'IL-12, l'IL-15 et IL-18), et un anticorps anti-NKp46.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201890121A EA038848B1 (ru) | 2015-06-24 | 2016-06-24 | Способ пролиферации естественных клеток-киллеров и композиции для пролиферации естественных клеток-киллеров |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150089882 | 2015-06-24 | ||
KR10-2015-0089882 | 2015-06-24 | ||
KR1020160078622A KR101909879B1 (ko) | 2015-06-24 | 2016-06-23 | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 |
KR10-2016-0078622 | 2016-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016209021A1 true WO2016209021A1 (fr) | 2016-12-29 |
Family
ID=57585970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/006754 WO2016209021A1 (fr) | 2015-06-24 | 2016-06-24 | Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016209021A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107974431A (zh) * | 2018-01-17 | 2018-05-01 | 北京汇智驰康生物科技有限公司 | 一种自然杀伤细胞的快速扩增方法 |
WO2020146795A1 (fr) * | 2019-01-11 | 2020-07-16 | Omeros Corporation | Procédés et compositions pour le traitement du cancer |
CN111849894A (zh) * | 2020-07-31 | 2020-10-30 | 南京元荟生物科技有限公司 | 一种肿瘤浸润淋巴细胞的分离方法及其应用 |
US11066644B2 (en) | 2018-02-01 | 2021-07-20 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
CN113528438A (zh) * | 2021-08-09 | 2021-10-22 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 基于表面活化受体和抑制受体表达的nk细胞数量扩增方法 |
WO2022060056A1 (fr) * | 2020-09-15 | 2022-03-24 | 주식회사 티에스바이오 | Procédé de préparation de cellules tueuses naturelles de grande pureté avec une efficacité élevée, et utilisation de celles-ci |
WO2022074206A1 (fr) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Lieurs trispécifiques |
US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
WO2023007023A1 (fr) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Corps duplex |
US11746327B2 (en) | 2017-11-24 | 2023-09-05 | Sungkwang Medical Foundation | Composition for culturing NK cells and method for culturing NK cells using same |
CN117487750A (zh) * | 2023-11-08 | 2024-02-02 | 青岛西凯生物技术有限公司 | Nk细胞在制备治疗免疫相关病症的药物中的用途 |
CN117551608A (zh) * | 2023-11-10 | 2024-02-13 | 深圳泽医细胞治疗集团有限公司 | 活化培养基、高分泌IFN-γ的NK细胞的培养方法及应用 |
WO2024056861A1 (fr) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Protéines de liaison à un antigène multispécifiques pour stimuler des cellules nk et utilisation associée |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100012586A (ko) * | 2008-07-29 | 2010-02-08 | 주식회사 녹십자 | 자연살해세포의 증식방법 |
JP2010220479A (ja) * | 2007-06-15 | 2010-10-07 | Medeinetto:Kk | Nk細胞の培養方法及びnk細胞の利用 |
KR20120090485A (ko) * | 2011-02-08 | 2012-08-17 | (주)차바이오앤디오스텍 | 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물 |
KR20140123503A (ko) * | 2011-12-22 | 2014-10-22 | 재단법인 목암생명공학연구소 | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 |
-
2016
- 2016-06-24 WO PCT/KR2016/006754 patent/WO2016209021A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010220479A (ja) * | 2007-06-15 | 2010-10-07 | Medeinetto:Kk | Nk細胞の培養方法及びnk細胞の利用 |
KR20100012586A (ko) * | 2008-07-29 | 2010-02-08 | 주식회사 녹십자 | 자연살해세포의 증식방법 |
KR20120090485A (ko) * | 2011-02-08 | 2012-08-17 | (주)차바이오앤디오스텍 | 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물 |
KR20140123503A (ko) * | 2011-12-22 | 2014-10-22 | 재단법인 목암생명공학연구소 | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 |
Non-Patent Citations (2)
Title |
---|
ANDRE, PASCALE ET AL.: "Comparative Analysis of Human NK Cell Activation Induced by NKG2D and Natural Cytotoxicity Receptors", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 34, no. 4, 2004, pages 961 - 971, XP055341057 * |
DE MARIA, ANDREA ET AL.: "Revisiting Human Natural Killer Cell Subset Function Revealed Cytolytic CD 56dimCD16+ NK Cells as Rapid Producers of Abundant IFN-gamma on Activation", PNAS, vol. 108, no. 2, 2011, pages 728 - 732, XP055196579 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11746327B2 (en) | 2017-11-24 | 2023-09-05 | Sungkwang Medical Foundation | Composition for culturing NK cells and method for culturing NK cells using same |
US11981924B2 (en) | 2017-11-24 | 2024-05-14 | Sungkwang Medical Foundation | Composition for culturing NK cells and method for culturing NK cells using same |
CN107974431B (zh) * | 2018-01-17 | 2020-06-30 | 北京汇智驰康生物科技有限公司 | 一种自然杀伤细胞的快速扩增方法 |
CN107974431A (zh) * | 2018-01-17 | 2018-05-01 | 北京汇智驰康生物科技有限公司 | 一种自然杀伤细胞的快速扩增方法 |
US11066644B2 (en) | 2018-02-01 | 2021-07-20 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
WO2020146795A1 (fr) * | 2019-01-11 | 2020-07-16 | Omeros Corporation | Procédés et compositions pour le traitement du cancer |
CN111849894A (zh) * | 2020-07-31 | 2020-10-30 | 南京元荟生物科技有限公司 | 一种肿瘤浸润淋巴细胞的分离方法及其应用 |
CN111849894B (zh) * | 2020-07-31 | 2024-04-26 | 南京元荟生物科技有限公司 | 一种肿瘤浸润淋巴细胞的分离方法及其应用 |
WO2022060056A1 (fr) * | 2020-09-15 | 2022-03-24 | 주식회사 티에스바이오 | Procédé de préparation de cellules tueuses naturelles de grande pureté avec une efficacité élevée, et utilisation de celles-ci |
WO2022074206A1 (fr) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Lieurs trispécifiques |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
WO2023007023A1 (fr) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Corps duplex |
CN113528438A (zh) * | 2021-08-09 | 2021-10-22 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 基于表面活化受体和抑制受体表达的nk细胞数量扩增方法 |
WO2024056861A1 (fr) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Protéines de liaison à un antigène multispécifiques pour stimuler des cellules nk et utilisation associée |
WO2024056862A1 (fr) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Protéines multispécifiques de liaison à l'antigène pour le ciblage tumoral de cellules nk et leur utilisation |
CN117487750A (zh) * | 2023-11-08 | 2024-02-02 | 青岛西凯生物技术有限公司 | Nk细胞在制备治疗免疫相关病症的药物中的用途 |
CN117551608A (zh) * | 2023-11-10 | 2024-02-13 | 深圳泽医细胞治疗集团有限公司 | 活化培养基、高分泌IFN-γ的NK细胞的培养方法及应用 |
CN117551608B (zh) * | 2023-11-10 | 2024-04-30 | 深圳泽医细胞治疗集团有限公司 | 活化培养基、高分泌IFN-γ的NK细胞的培养方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016209021A1 (fr) | Méthode pour faire proliférer des cellules tueuses naturelles et composition pour faire proliférer des cellules tueuses naturelles | |
KR101909879B1 (ko) | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 | |
EP3307875B1 (fr) | Procédés pour la production de lymphocytes t tcr gamma delta+ | |
WO2017142187A1 (fr) | Kit d'addition de milieu pour la culture de cellules nk et procédé de culture de cellules nk (cellules tueuses naturelles) utilisant le kit | |
WO2016085248A1 (fr) | Procédé de culture de cellules tueuses naturelles à l'aide de lymphocytes t | |
WO2018097540A2 (fr) | Kit à ajout de milieu de culture de cellules immunitaires sans sérum, méthode de culture de cellules immunitaires utilisant ledit kit, culture de cellules immunitaires sans sérum obtenue au moyen dudit kit ou de ladite méthode de culture, et composition cosmétique comprenant ladite culture | |
WO2010013947A2 (fr) | Procédé de développement de cellules tueuses naturelles | |
WO2013094988A1 (fr) | Procédé pour produire des cellules tueuses naturelles, cellules tueuses naturelles produites de cette façon, et composition pour traiter des cancers et des maladies infectieuses contenant les mêmes | |
CN110914410A (zh) | γδT细胞扩增、组合物及其使用方法 | |
JP6073417B2 (ja) | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 | |
WO2019117633A1 (fr) | Composition cosmétique et composition pharmaceutique pour atténuer la dermatite atopique, la chute des cheveux et les plaies ou réduire les rides de la peau | |
WO2006107101A1 (fr) | Processus de production de cellule t regulatrice | |
KR20220119611A (ko) | 천연 살해 세포의 제조 방법 및 이의 조성물 | |
WO2017146538A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par des lymphocytes t régulateurs | |
RU2391401C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ | |
WO2017003153A1 (fr) | Méthode de production de cellules tueuses naturelles à partir de monocytes de sang de cordon ombilical, ou de cellules dérivées de ces derniers | |
JPH04325087A (ja) | Cd4+ヘルパーt細胞の産生方法 | |
KR101867942B1 (ko) | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 | |
WO2016117960A1 (fr) | Cellules souches mésenchymateuses surexprimées par grim19 efficaces dans le traitement d'une maladie immunitaire, et leur utilisation | |
WO2019103436A9 (fr) | Composition pour la culture de cellules nk et procédé pour la culture de cellules nk l'utilisant | |
WO2020213972A1 (fr) | Cellules tueuses naturelles présentant une activité anticancéreuse accrue et leur utilisation immunothérapeutique | |
WO2020032782A1 (fr) | Procédé de préparation et de cryoconservation de cellules t cd8+ spécifiques d'un antigène cancéreux | |
WO2020231205A1 (fr) | Composition pour la culture de cellules tueuses naturelles, et procédé l'utilisant | |
Cong et al. | Interleukin-2 Enhances the Regulatory Functions of CD4+ T Cell-Derived CD4− CD8− Double Negative T Cells | |
WO2022080894A1 (fr) | Cellule tueuse naturelle ayant une expression régulée d'un gène ayant une utilité oncologique, et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16814734 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201890121 Country of ref document: EA |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16814734 Country of ref document: EP Kind code of ref document: A1 |